Clinical trials: Dermatitis Atopic
Psoriasis, Atopic Dermatitis
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.
- Trial name
- NCT03381625
- Testing
- BMX-010
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- BioMimetix JV, LLC
Atopic Dermatitis (AD)
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epidermal activation, dysbiosis and epidermal…
- Trial name
- NCT03389893
- Testing
- Dupilumab
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis.
- Trial name
- NCT04271514
- Testing
- RPT193
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 103 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Atopic Dermatitis
EARLYEMOLLIENT - Feasibility of Early Emollient Use in Children With Atopic Eczema
The aim of this pragmatic, parallel group, assessor-blind randomised open-label prospective study is to determine the reasons that motivate parents to enrol or not enrol their child in a randomized, controlled basic emollient…
- Trial name
- EARLYemo (NCT03376243)
- Testing
- LIPIKAR BAUME AP+ emollient
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Mild to Moderate Atopic Dermatitis
A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis
Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the treatment of mild to moderate Atopic Dermatitis (AD) adults.
- Trial name
- NCT05057351
- Testing
- Isopentenyltheophylline 0.44% + Glycerin 4.56%, Glycerin 4.56%
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Greenpharma S.A.S.
Dermatitis, Dermatitis, Atopic
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- NCT03627767
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 1,235 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes
Atopic eczema is a common skin disorder affecting at least 2-3% of the western population. Atopic eczema cannot be cured and therefore treatment aims to alleviate the symptoms of the disease.
- Conditions
- Atopic Dermatitis, Eczema, DNA
- Trial name
- NCT04965233
- Testing
- DNA reports, Information reports
- Where
- 2 sites in United States, Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Studies&Me
Atopic Dermatitis
Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence
Atopic dermatitis is a chronic inflammatory skin disease often occurring in childhood. The treatment consists in making daily local treatment with topical steroid on inflammatory lesions and emollient on the whole body.
- Trial name
- DACE (NCT02193230)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Nantes University Hospital
Atopic Dermatitis Eczema
Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis
A Phase 2, multicenter, double-blind, placebo control study evaluating the safety and efficacy of Thykamine in adult patient suffering of mild-to-moderate Atopic Dermatitis
- Trial name
- NCT03540043
- Testing
- Administration of PUR0110 (Thykamine) 0.05%, Administration of PUR0110 (Thykamine) 0.1%, Administration of PUR0110 (Thykamine) 0.25%
- Where
- 12 sites in Canada
- Volunteers
- 162 people
- Sponsor
- PurGenesis Technologies Inc.
Atopic Dermatitis
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04504279
- Testing
- FB-401
- Where
- 15 sites in United States
- Volunteers
- 154 people
- Sponsor
- Forte Biosciences, Inc.
Allergic Asthma, Allergic Rhinitis
Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis
The prevalence of allergic diseases (atopic dermatitis, asthma, rhinitis, conjunctivitis and food allergy) has increased dramatically in industrialized countries over the last 20-30 years.
- Conditions
- Allergic Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- Prévall-DP (NCT02908360)
- Testing
- double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Nantes University Hospital
Dermatitis, Atopic
Effect of Different Skin Creams on TEWL
Prospective, single center, clinical pilot study to test the hypothesis that lipid rich EpiCeram® is superior in improving skin barrier function compared to Aveeno Daily Moisturising Sheer Hydration Lotion®.
- Trial name
- NCT03663673
- Testing
- EpiCeram, Aveeno Daily Moisturising Sheer Hydration Lotion®
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Atopic Dermatitis (AD)
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects
The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).
- Trial name
- NCT04056130
- Testing
- KBL697
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- KoBioLabs
Atopic Dermatitis
A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and a Lip Moisturizer in Adults of Atopic Dermatitis.
This study will test the safety and efficacy of 2 moisturizers: a body lotion and a lip moisturizer. For the moisturizer body lotion, the study aims to determine the tolerance of this product by the study population, and its…
- Trial name
- NCT04950374
- Testing
- Moisturizer Body Lotion, Lip Moisturizer
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Dermatitis, Atopic
China Atopic Dermatitis Registry Study
This regestry study is aimed to characterize the medical care and drug treatment under real-life conditions among Chinese patients with moderate to severe Atopic Dermatitis who are not well controlled by topical therapies.
- Trial name
- NCT05023668
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Peking University People's Hospital
Dermatitis, Atopic
Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis
This study is being conducted to evaluate the efficacy and safety of 3 different application rates of topically applied Crisaborole ointment 2% over vehicle in adults with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT03868098
- Testing
- Crisaborole 2%
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Innovaderm Research Inc.
Dermatitis, Atopic
NMF-CsA-Dupi Trial
The goal of this study is to investigate whether stratification of children with atopic dermatitis on the NMF biomarkers results in an improvement of effectiveness and efficiency in the use of systemic treatment (ciclosporin and…
- Trial name
- NCT04878770
- Testing
- Topical corticosteroids, Systemic cyclosporine, Systemic dupilumab
- Where
- Netherlands
- Volunteers
- 318 people
- Sponsor
- Erasmus Medical Center
Dermatitis, Atopic
Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)
This clinical trial study is two-stage, multi-center, randomized, double-blind, placebo controlled, phase 3 clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis.
- Trial name
- smart(FURIN) (NCT05004324)
- Testing
- FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
- Where
- South Korea
- Volunteers
- 308 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
This study is a Phase 3, multicenter, open-label, long-term safety extension study of Studies C3291032 and C3291031 in Japanese pediatric and adult participants with mild to moderate Atopic Dermatitis (AD).
- Trial name
- NCT04498403
- Testing
- Crisaborole 2%
- Where
- 11 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Asthma, Allergic Rhinitis
Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics.
- Conditions
- Asthma, Allergic Rhinitis, Conjunctivitis, Atopic Dermatitis
- Trial name
- NCT04984941
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine